Want to see LNTH full AI Analyst Report?
LNTH Stock Chart & Stats
$100.87
$3.21(3.06%)
At close: 4:00 PM EDT
$100.87
$3.21(3.06%)
Day’s Range― - ―
52-Week Range$49.67 - $111.86
Previous Close$117
Volume1.07M
Average Volume (3M)1.80M
Market Cap
$6.59B
Enterprise Value$7.52K
Total Cash (Recent Filing)$593.30M
Total Debt (Recent Filing)$624.96M
Price to Earnings (P/E)24.0
Beta0.42
Next Earnings
Oct 29, 2026EPS Estimate
1.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.21
Shares Outstanding65,272,370
10 Day Avg. Volume1,201,765
30 Day Avg. Volume1,797,943
Financial Highlights & Ratios
PEG Ratio-0.82
Price to Book (P/B)4.12
Price to Sales (P/S)2.91
P/FCF Ratio12.69
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$105.40Price Target Upside4.49% Upside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)5.37
Revenue Forecast (FY)$1.48B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationRobust operating and free cash flow gives Lantheus internal funding for manufacturing, research, launches and acquisitions. Strong cash conversion also improves resilience against reimbursement pressure, competitive pricing and temporary earnings volatility.
Established Product FranchisesLeading positions in cardiac imaging and prostate-cancer diagnostics, alongside growing neurology adoption, provide scale and customer familiarity. The diversified portfolio can support durable demand even when one product faces competition or pricing pressure.
Expanded Diagnostic CapabilityTauklarify expands Lantheus’ addressable market beyond cardiac and oncology imaging into Alzheimer’s diagnostics. Regulatory approval supports commercialization, strengthens the neurology platform and creates potential for broader clinical adoption over time.
Bears Say
PSMA PET Pricing PressurePYLARIFY remains a major revenue driver, so sustained competition and lower net pricing could limit growth and compress contribution margins. Volume gains may not fully offset pricing erosion as competing PSMA PET products expand.
Profitability And Cost PressureLower operating profit alongside higher acquisition, launch and research spending indicates near-term margin dilution. If investments take longer to produce revenue, earnings conversion and sustained profitability could remain under pressure.
Regulatory And Launch Timing RiskDelays or unresolved legal issues can postpone commercial launches and defer pipeline revenue. Regulatory uncertainty also increases development costs and makes the timing of future radiopharmaceutical growth less predictable.
Lantheus News
LNTH FAQ
What was Lantheus’s price range in the past 12 months?
Lantheus lowest stock price was $49.67 and its highest was $111.86 in the past 12 months.
What is Lantheus’s market cap?
Lantheus’s market cap is $6.59B.
When is Lantheus’s upcoming earnings report date?
Lantheus’s upcoming earnings report date is Oct 29, 2026 which is in 54 days.
How were Lantheus’s earnings last quarter?
Lantheus released its earnings results on Aug 06, 2026. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.304 by $0.246.
Is Lantheus overvalued?
According to Wall Street analysts Lantheus’s price is currently Undervalued.
Does Lantheus pay dividends?
Lantheus does not currently pay dividends.
What is Lantheus’s EPS estimate?
Lantheus’s EPS estimate is 1.26.
How many shares outstanding does Lantheus have?
Lantheus has 65,272,370 shares outstanding.
What happened to Lantheus’s price movement after its last earnings report?
Lantheus reported an EPS of $1.55 in its last earnings report, beating expectations of $1.304. Following the earnings report the stock price went down -0.424%.
Which hedge fund is a major shareholder of Lantheus?
Currently, no hedge funds are holding shares in LNTH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantheus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$105.40 (4.49% Upside)
$105.40 (4.49% Upside)
Blogger Sentiment
Neutral
LNTH Sentiment 50%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 336.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 7.9%
Last 30 Days ▼ 7.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.10%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lantheus
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.
LNTH Company Deck
LNTH Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call contained meaningful positives — regulatory progress with PYLARIFY TRUVU approval, solid cash generation, NEUROCEQ and DEFINITY growth, and a reaffirmed full-year outlook — balanced against near-term profitability pressure driven by lower oncology reported revenue, higher operating expenses from recent acquisitions and investments, competitive and pricing risks in PSMA PET, and regulatory timing uncertainty for some therapeutic assets. Management emphasized disciplined capital allocation and readiness to launch TRUVU, and expects growth acceleration in 2027, but near-term headwinds keep the tone measured.View all LNTH earnings summariesLNTH Revenue Breakdown
65.91% Radiopharmaceutical oncology
30.09% Precision diagnostics
4.00% Strategic Partnerships and other revenue
LNTH Stock 12 Month Forecast
Average Price Target
$105.40
▲(4.49% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
1.83% Insiders
34.74% Mutual Funds
28.51% Other Institutional Investors
3.65% Public Companies and
Individual Investors